Literature DB >> 7733867

Human mast cell tryptase isoforms: separation and examination of substrate-specificity differences.

S S Little1, D A Johnson.   

Abstract

Tryptases are trypsin-like enzymes found in mast cell granules that appear to exist as tetramers. These enzymes are not controlled by blood plasma proteinase inhibitors and only cleave a few physiological substrates in vitro, including high-molecular-mass kininogen (HMMK) and vasoactive intestinal peptide (VIP). Purified human lung mast cell tryptase (HLT) contained two bands of approx. molecular mass 29 and 33 kDa on SDS/PAGE. These two forms of HLT have been separated by chromatography on a cellulose phosphate column, with the high-molecular-mass form (high-HLT) being eluted with 10 microM heparin and the low-molecular-mass form (low-HLT) subsequently eluted with 1 M NaCl. Removal of asparagine-linked carbohydrate caused both isoforms to run as single sharp bands on SDS/PAGE, differing slightly in molecular mass. Separation of these two isoforms of tryptase shows that tetramers consist of four homologous subunits rather than mixtures of the two isoforms. Using HMMK and VIP as substrates, these two forms of HLT were found to differ with regard to specificity and rate of cleavage. High-HLT initially cleaved HMMK at Arg-431 within the C-terminal anionic binding region of the molecule, whereas low-HLT cleaved HMMK simultaneously at multiple sites within the C-terminal portion of the molecule. On the basis of HPLC peptide mapping, each isoform also cleaved VIP at different sites. Comparison of cleavage rates based on the active-site concentrations of titrated isoforms showed that low-HLT cleaved HMMK more rapidly than did high-HLT. These two isoforms may represent different gene products or they may result from post-translational modification.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7733867      PMCID: PMC1136654          DOI: 10.1042/bj3070341

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  28 in total

1.  Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininogens.

Authors:  Y Takagaki; N Kitamura; S Nakanishi
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

2.  Determination of the operational molarity of solutions of bovine alpha-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration.

Authors:  G W Jameson; D V Roberts; R W Adams; W S Kyle; D T Elmore
Journal:  Biochem J       Date:  1973-01       Impact factor: 3.857

Review 3.  Vasoactive intestinal polypeptide (VIP): current status.

Authors:  S I Said
Journal:  Peptides       Date:  1984 Mar-Apr       Impact factor: 3.750

4.  Vasoactive intestinal peptide as a bronchodilator in asthmatic subjects.

Authors:  A H Morice; R J Unwin; P S Sever
Journal:  Peptides       Date:  1984 Mar-Apr       Impact factor: 3.750

5.  The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans.

Authors:  P J Barnes; C M Dixon
Journal:  Am Rev Respir Dis       Date:  1984-08

6.  Human lung tryptase. Purification and characterization.

Authors:  T J Smith; M W Hougland; D A Johnson
Journal:  J Biol Chem       Date:  1984-09-10       Impact factor: 5.157

7.  Expression of a mast cell tryptase in the human monocytic cell lines U-937 and Mono Mac 6.

Authors:  R Huang; M Abrink; A E Gobl; G Nilsson; M Aveskogh; L G Larsson; K Nilsson; L Hellman
Journal:  Scand J Immunol       Date:  1993-10       Impact factor: 3.487

8.  Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells.

Authors:  L B Schwartz; R A Lewis; D Seldin; K F Austen
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Inactivation of human high molecular weight kininogen by human mast cell tryptase.

Authors:  M Maier; J Spragg; L B Schwartz
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

10.  Tryptase from human pulmonary mast cells. Purification and characterization.

Authors:  L B Schwartz; R A Lewis; K F Austen
Journal:  J Biol Chem       Date:  1981-11-25       Impact factor: 5.157

View more
  5 in total

1.  The structure of the human betaII-tryptase tetramer: fo(u)r better or worse.

Authors:  C P Sommerhoff; W Bode; P J Pereira; M T Stubbs; J Stürzebecher; G P Piechottka; G Matschiner; A Bergner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Expression of kininogens in the connective tissue-type mast cells of the rat.

Authors:  K Hosoi; S Matsuura; K Tsumura; W Wei; M N Parvin; J Tada; T Akamatsu; N Kanamori; K Suzuki
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

3.  Distinct expression of mast cell tryptase and protease activated receptor-2 in synovia of rheumatoid arthritis and osteoarthritis.

Authors:  Shunji Nakano; Takuya Mishiro; Shigeyuki Takahara; Hiromichi Yokoi; Daisuke Hamada; Kiminori Yukata; Yoichiro Takata; Tomohiro Goto; Hiroshi Egawa; Susumu Yasuoka; Harumi Furouchi; Katsuya Hirasaka; Takeshi Nikawa; Natsuo Yasui
Journal:  Clin Rheumatol       Date:  2007-01-05       Impact factor: 3.650

4.  Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator.

Authors:  L E Goldfinger; M S Stack; J C Jones
Journal:  J Cell Biol       Date:  1998-04-06       Impact factor: 10.539

5.  Mast cell tryptase and asthma.

Authors:  M Q Zhang; H Timmerman
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.